In malignancy, tumour cells can overcome the cytostatic effects of TGF‐β signalling, mostly by acquiring mutations in the canonical signalling components (eliminating the tumour suppressor function) or by adaptation of TGF‐β signalling through non‐canonical signalling (leading to tumour promoting effects) (22–24). This evidence concerns the gene TGFB1 and neoplasm.